Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
ETFs with DXCM as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.64%||iShares Enhanced U.S. Small-Cap (IESM)||-2.23 (-6.90%)|
|0.92%||iShares Morningstar Small-Cap Growth ETF (JKK)||-10.53 (-7.37%)|
|0.51%||iShares Russell 2000 Growth ETF (IWO)||-14.17 (-9.36%)|
|0.49%||Vanguard Russell 2000 Growth ETF (VTWG)||-10.47 (-9.50%)|
|0.26%||iShares Russell 2000 ETF (IWM)||-11.30 (-9.13%)|
Company Description (as filed with the SEC)
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms "we," "us," "our," the "company," or "DexCom" refer to DexCom, Inc. and its subsidiaries. Products Ambulatory Product Line: SEVEN® PLUS, DexCom G4®, DexCom G4® PLATINUM, and DexCom ShareTM System We received approval from the Food and Drug Administration ("FDA") and commercialized our first product in 2006. In 2007, we received approval and began commercializing our second generation system, the DexCom SEVEN. In 2009 we received approval and began commercializing our third generation system, the DexCom SEVEN PLUS. We no longer market or provide support for the DexCom SEVEN or SEVEN PLUS systems. ... More ...
Where does DXCM fit in the risk graph?
|Annual EPS Est:||$-0.3|
|Quarterly EPS Est:||0|